1. Efficacy of i-Factor Bone Graft versus Autograft in Anterior Cervical Discectomy and Fusion
- Author
-
Paul M. Arnold, Ashvin I. Patel, Joseph D. Smucker, Alexander R. Vaccaro, Robert F. Heary, Michael G. Fehlings, Benoit Goulet, Rick C. Sasso, Michael Janssen, Branko Kopjar, and Iain H. Kalfas
- Subjects
Adult ,Male ,medicine.medical_specialty ,Anterior cervical discectomy and fusion ,Bone healing ,Investigational device exemption ,Transplantation, Autologous ,Degenerative disc disease ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Device Approval ,Humans ,Medicine ,Single-Blind Method ,Orthopedics and Sports Medicine ,Prospective Studies ,Radiculopathy ,Prospective cohort study ,030222 orthopedics ,Bone Transplantation ,United States Food and Drug Administration ,business.industry ,Middle Aged ,medicine.disease ,United States ,Surgery ,Transplantation ,Spinal Fusion ,Treatment Outcome ,Orthopedic surgery ,Cervical Vertebrae ,Female ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Diskectomy - Abstract
STUDY DESIGN A prospective, randomized, controlled, parallel, single-blinded noninferiority multicenter pivotal FDA IDE trial. OBJECTIVE The objective of this study was to investigate efficacy and safety of i-Factor Bone Graft (i-Factor) compared with local autograft in single-level anterior cervical discectomy and fusion (ACDF) for cervical radiculopathy. SUMMARY OF BACKGROUND DATA i-Factor is a composite bone substitute material consisting of the P-15 synthetic collagen fragment adsorbed onto anorganic bone mineral and suspended in an inert biocompatible hydrogel carrier. P-15 has demonstrated bone healing efficacy in dental, orthopedic, and nonhuman applications. METHODS Patients randomly received either autograft (N = 154) or i-Factor (N = 165) in a cortical ring allograft. Study success was defined as noninferiority in fusion, Neck Disability Index (NDI), and Neurological Success endpoints, and similar adverse events profile at 12 months. RESULTS At 12 months (follow-up rate 87%), both i-Factor and autograft subjects demonstrated a high fusion rate (88.97% and 85.82%, respectively, noninferiority P = 0.0004), significant improvements in NDI (28.75 and 27.40, respectively, noninferiority P
- Published
- 2016